Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Lipella Pharmaceuticals, Inc. ( (LIPO) ).
On May 12, 2025, Lipella Pharmaceuticals received a notice from Nasdaq indicating non-compliance with certain listing rules due to its issuance of Series C voting convertible preferred stock and warrants between December 2024 and March 2025. The company plans to address these deficiencies by responding to the Nasdaq Hearings Panel by May 19, 2025, and taking necessary actions, including holding an annual meeting of stockholders. The notice does not immediately affect the company’s stock listing, but there is uncertainty about regaining compliance and maintaining future listing standards.
The most recent analyst rating on (LIPO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.
More about Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is involved in private placement transactions and issues convertible preferred stock and warrants as part of its financial strategies.
Average Trading Volume: 94,843
Technical Sentiment Signal: Sell
Current Market Cap: $6.09M
Find detailed analytics on LIPO stock on TipRanks’ Stock Analysis page.